Gastrointestinal Bleeding in Patients with Coronary Heart Disease: Preventive Options

Extensive use of antithrombotic drugs (ATD) in patients with ischemic heart disease (IHD), on the one hand, provides a considerable decrease in the risk for development of life-threatening cardiovascular complications but on the other hand, is associated with a risk of gastrointestinal bleedings (GIB), which may develop in 0.5-1.0 % of patients. In such cases, the major measures for prevention of GIB are strict adherence to indications for the ATD treatment, detection and analysis of risk factors for GIB and their elimination as far as feasible. For evaluation of GIB risk in patients with IHD, the PRECISE-DAPT and DAPT, HAS-BLED scales should be used. If the risk factors are non-modifiable the therapeutic tactics for further management of these patients should be strictly individual with determining the nature of damage, degree of a risk for present and possible complications, and the range of required therapeutic and diagnostic measures. The use of ATD requires monitoring of the patient’s condition to timely detect and treat GI complications.

1. Moroz E.V., Artemkin E.N., Kryukov E.V., Chernetsov V.A. Gastro-Intestinal Tract Complications During Antithrombotic Therapy. General Reanimatology. 2018;14(3):15–26. DOI: 10.15360/1813-9779-2018-3-15-26

2. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery. 2018;53(1):34–78. DOI: 10.1093/ejcts/ezx334

3. Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, MarquisGravel G, Robinson SD et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology. 2018;34(3):214–33. DOI: 10.1016/j.cjca.2017.12.012

4. Siller-Matula JM, Huber K, Christ G, Schror K, Kubica J, Herkner H et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2011;97(2):98–105. DOI: 10.1136/hrt.2010.195438

5. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationClinical Perspective: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation. 2011;123(21):2363–72. DOI: 10.1161/CIRCULATIONAHA.110.004747

6. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 2009;361(24):2342–52. DOI: 10.1056/NEJMoa0906598

7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369(22):2093–104. DOI: 10.1056/NEJMoa1310907

9. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039

10. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 2017;15(11):1674-1683.e3. DOI: 10.1016/j.cgh.2017.04.031

11. Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Yeganyan R.A. et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;23(6):7–122. DOI: 10.15829/1560-4071-2018-6-7-122

12. GUSTO Investigators. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. New England Journal of Medicine. 1993;329(10):673–82. DOI: 10.1056/NEJM199309023291001

13. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL et al. Thrombolysis in myocardial infarction (TIMI) trial – Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Journal of the American College of Cardiology. 1988;11(1):1–11. DOI: 10.1016/0735-1097(88)90158-1

14. Serebruany VL, Atar D. Assessment of Bleeding Events in Clinical Trials – Proposal of a New Classification. The American Journal of Cardiology. 2007;99(2):288–90. DOI: 10.1016/j.amjcard.2006.07.091

15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. DOI: 10.1378/chest.10-0134

16. Vicente V, Martín A, Lecumberri R, Coll-Vinent B, Suero C, González-Porras JR et al. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal). Emergencias: Revista De La Sociedad Espanola De Medicina De Emergencias. 2017;29(1):18–26. PMID: 28825264

17. Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opinion on Drug Safety. 2017;16(6):673–85. DOI: 10.1080/14740338.2017.1325870

18. Albaladejo P, Samama C-M, Sié P, Kauffmann S, Mémier V, Suchon P et al. Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis. Anesthesiology. 2017;127(1):111–20. DOI: 10.1097/ALN.0000000000001631

19. Lauffenburger JC, Rhoney DH, Farley JF, Gehi AK, Fang G. Predictors of Gastrointestinal Bleeding Among Patients with Atrial Fibrillation After Initiating Dabigatran Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015;35(6):560–8. DOI: 10.1002/phar.1597

20. Ivashkin V.T., Sheptulin A.A., Mayev I.V., Baranskaya Ye.K., Trukhmanov A.S., Lapina T.L. Russian gastroenterological association clinical guidelines on diagnostics and treatment of NSAIDs-associated erosive and ulcerative lesions of the stomach and duodenum. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(5):89–94.

21. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. DOI: 10.1136/gutjnl-2016-312288

22. Karateev A.E., Nasonov E.L., Yakhno N.N., Ivashkin V.T., Chichasova N.V., Alekseeva L.I. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Modern Rheumatology Journal. 2015;9(1):4– 23. DOI: 10.14412/1996-7012-2015-1-4-23

23. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117(1):17–25. PMID: 10381905

24. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. DOI: 10.1136/bmj.324.7329.71

25. Cooke AR, Hunt JN. Absorption of acetylsalicylic acid from unbuffered and buffered gastric contents. The American Journal of Digestive Diseases. 1970;15(2):95–102. PMID: 4905590

26. Graham DY. Aspirin and the Stomach. Annals of Internal Medicine. 1986;104(3):390–8. DOI: 10.7326/0003-4819-104-3-390

27. Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal Tolerance of 75 mg Clopidogrel versus 325 mg Aspirin in Healthy Volunteers: A Gastroscopic Study. Scandinavian Journal of Gastroenterology. 2000;35(5):464–9. DOI: 10.1080/003655200750023705

28. Kirichenko A.A., Ebzeeva E.Iu. Acetylsalicylic acid in the secondary prevention of cardiovascular complications. Consilium Medicum. 2019;21(5):28–31. DOI: 10.26442/20751753.2019.5.190454

29. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. The Lancet. 2007;369(9561):614. DOI: 10.1016/ S0140-6736(07)60282-7

30. Endo H, Sakai E, Kato T, Umezawa S, Higurashi T, Ohkubo H et al. Small bowel injury in low-dose aspirin users. Journal of Gastroenterology. 2015;50(4):378–86. DOI: 10.1007/s00535-014-1028-x

31. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T et al. Small Bowel Injury by Low-Dose EntericCoated Aspirin and Treatment With Misoprostol: A Pilot Study. Clinical Gastroenterology and Hepatology. 2008;6(11):1279– 82. DOI: 10.1016/j.cgh.2008.06.021

32. Smecuol E, Pinto Sanchez MI, Suarez A, Argonz JE, Sugai E, Vazquez H et al. Low-Dose Aspirin Affects the Small Bowel Mucosa: Results of a Pilot Study With a Multidimensional Assessment. Clinical Gastroenterology and Hepatology. 2009;7(5):524–9. DOI: 10.1016/j.cgh.2008.12.019

33. Utzeri E, Usai P. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2017;23(22):3954–63. DOI: 10.3748/wjg.v23.i22.3954

34. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W et al. Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis. Gastroenterology. 2011;141(4):1314-1322.e5. DOI: 10.1053/j.gastro.2011.06.075

35. Endo H, Sakai E, Taniguchi L, Kessoku T, Komiya Y, Ezuka A et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointestinal Endoscopy. 2014;80(5):826–34. DOI: 10.1016/j.gie.2014.03.024

36. Karateev A.E., Moroz E.V., Kryukov E.V. Small intestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. Almanac of Clinical Medicine. 2019;47(6):559–67. DOI: 10.18786/2072-0505-2019-47-048

37. Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology. 2018;154(3):500–14. DOI: 10.1053/j.gastro.2017.10.049

38. Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1–29. DOI: 10.14412/1995-4484-2018-1-29

39. Writing Committee Members, Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894–909. DOI: 10.1161/CIRCULATIONAHA.108.191087

40. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine. 2009;361(11):1045–57. DOI: 10.1056/NEJMoa0904327

41. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. The Lancet. 2009;373(9665):723–31. DOI: 10.1016/S0140-6736(09)60441-4

42. Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World Journal of Gastroenterology. 2017;23(11):1954– 63. DOI: 10.3748/wjg.v23.i11.1954

43. Desai J, Kolb J, Weitz J, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. Thrombosis and Haemostasis. 2013;110(08):205–12. DOI: 10.1160/TH13-02-0150

44. Kundu A, Sardar P, Sen P, Chatterjee S, Huston J, Nairooz R et al. Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. Journal of Atrial Fibrillation. 2015;8(3):1218. DOI: 10.4022/jafib.1218

45. Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy. 2013;78(2):227–39. DOI: 10.1016/j.gie.2013.04.179

46. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metabolism and Disposition. 2008;36(2):386–99. DOI: 10.1124/dmd.107.019083

47. Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y et al. Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics: Dabigatran-induced esophagitis. Journal of Gastroenterology and Hepatology. 2016;31(3):610–4. DOI: 10.1111/jgh.13024

48. Thomopoulos KC. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: Endoscopic findings, clinical management and outcome. World Journal of Gastroenterology. 2005;11(9):1365–8. DOI: 10.3748/wjg.v11.i9.1365

49. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointestinal Endoscopy. 2003;58(3):369–73. PMID: 14528210

50. Endo H, Hosono K, Inamori M, Nozaki Y, Yoneda K, Fujita K et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. Journal of Gastroenterology. 2009;44(6):544–9. DOI: 10.1007/s00535-009-0040-z

51. Balabantseva A.P., Karateev A.E. The frequency and clinical and endoscopic features of mixed NSAIDs-induced gastrointestinal injuries. Modern Rheumatology Journal. 2018;12(4):95– 100. DOI: 10.14412/1996-7012-2018-4-95-100

52. Vakhrushev N.M., Zagrebina E.A. Enteropathy induced by nonsteroidal anti-inflammatory drugs (pathogenesis, diagnosis, treatment). Therapeutic Archive. 2012;84(5):74–9.

53. Rao SV, Eikelboom J, Steg PhG, Lincoff AM, Weintraub WS, Bassand J-P et al. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal. 2009;158(6):881-886.e1. DOI: 10.1016/j.ahj.2009.10.008

54. Flack KF, Desai J, Kolb JM, Chatterjee P, Wallentin LC, Ezekowitz M et al. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clinical Gastroenterology and Hepatology. 2017;15(5):682–90. DOI: 10.1016/j.cgh.2016.10.011

55. Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Practice & Research Clinical Gastroenterology. 2010;24(2):121–32. DOI: 10.1016/j.bpg.2009.11.005

56. Baranovsky A.Yu. Diagnosis, prevention and treatment of NSAID-induced colonopathy. Experimental and Clinical Gastroenterology. 2017;10:4–14. DOI: 10.31146/1682-8658-ecg

57. Tai FWD, McAlindon ME. NSAIDs and the small bowel: Current Opinion in Gastroenterology. 2018;34(3):175–82. DOI: 10.1097/MOG.0000000000000427

58. Sands G, Shell B, Zhang R. Adverse Events in Patients with Blood Loss: A Pooled Analysis of 51 Clinical Studies from the Celecoxib Clinical Trial Database. The Open Rheumatology Journal. 2012;6(1):44–9. DOI: 10.2174/1874312901206010044

59. Kanorskii S.G., Gilyarevskii S.R., Tarasov A.V., Zhuk V.S., Yavelov I.S. New EHRA guidelines on anticoagulant therapy in patients with atrial fibrillation: comments of Russian expert. International Heart and Vascular Disease Journal. 2018;6(19):44–56.

60. Lazebnik L.B., Golovanova E.V., Alekseenko S.A., Bakulina N.V., Baranovsky A.Yu., Belova G.V. et al. Recommendations for the prevention and treatment of esophagogastro-entero-colopathy induced by nonsteroidal antiinfl ammatory drugs “NSAID”. Experimental and Clinical Gastroenterology. 2018;3:4–18. DOI: 10.31146/1682-8658-ecg

61. Moroz E.V., Karateev A.E., Kryukov E.V., Chernetsov V.A. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Rheumatology Science and Practice. 2017;55(6):675–84. DOI: 10.14412/1995-4484-2017-675-684

62. Radaelli F, Dentali F, Repici A, Amato A, Paggi S, Rondonotti E et al. Management of anticoagulation in patients with acute gastrointestinal bleeding. Digestive and Liver Disease. 2015;47(8):621–7. DOI: 10.1016/j.dld.2015.03.029

63. Sugano K, Choi M-G, Lin J-T, Goto S, Okada Y, Kinoshita Y et al. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study. Gut. 2014;63(7):1061–8. DOI: 10.1136/gutjnl-2013-304722

64. Scheiman JM, Lanas A, Veldhuyzen van Zanten S, Baldycheva I, Svedberg L-E, Nagy P. Effect of esomeprazole on gastroduodenal erosions in patients at increased gastrointestinal risk treated with low-dose acetylsalicylic acid: A post-hoc analysis of the OBERON trial. International Journal of Cardiology. 2015;182:500–2. DOI: 10.1016/j.ijcard.2014.12.140

65. Mo C. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World Journal of Gastroenterology. 2015;21(17):5382–92. DOI: 10.3748/wjg.v21.i17.5382

66. Niu Q, Wang Z, Zhang Y, Wang J, Zhang P, Wang C et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics. 2017;22(2):142–52. DOI: 10.1177/1074248416663647

67. Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith L-A et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Gut. 2016;65(3):374–89. DOI: 10.1136/gutjnl-2015-311110

68. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. New England Journal of Medicine. 1998;338(11):727–34. DOI: 10.1056/NEJM199803123381105

69. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ et al. A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. New England Journal of Medicine. 1998;338(11):719–26. DOI: 10.1056/NEJM199803123381104

70. Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya Ye.K. et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology Hepatology and Coloproctology. 2018;28(1):55–70. DOI: 10.22416/1382-4376-2018-28-1-55-70

71. Karateev A.E., Nasonov E.L., Uspensky Yu.P., Pakhomova I.G. Combined treatment of gastric ulcers induced by non-steroidal anti-inflammatory drugs. Results of a 4-week open-label controlled trial evaluating the effectiveness of the combination of a proton pump inhibitor and bismuth tripotassium dicitrate. Therapeutic Archive. 2009;81(6):62–7.

72. Mizukami K. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World Journal of Gastroenterology. 2011;17(46):5117–22. DOI: 10.3748/wjg.v17.i46.5117

73. Tozawa K, Oshima T, Okugawa T, Ogawa T, Ohda Y, Tomita T et al. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Digestive Diseases and Sciences. 2014;59(8):1885–90. DOI: 10.1007/s10620-014-3108-4

74. Kurokawa S, Katsuki S, Fujita T, Saitoh Y, Ohta H, Nishikawa K et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. Journal of Gastroenterology. 2014;49(2):239–44. DOI: 10.1007/s00535-013-0805-2

75. Watanabe T, Takeuchi T, Handa O, Sakata Y, Tanigawa T, Shiba M et al. A Multicenter, Randomized, Double-Blind, PlaceboControlled Trial of High-Dose Rebamipide Treatment for LowDose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage. PLOS ONE. 2015;10(4):e0122330. DOI: 10.1371/journal.pone.0122330

76. Lim YJ, Chun HJ. Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges. Gastroenterology Research and Practice. 2013;2013:761060. DOI: 10.1155/2013/761060

77. Fornai M, Antonioli L, Pellegrini C, Colucci R, Sacco D, Tirotta E et al. Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacological Research. 2016;104:186–96. DOI: 10.1016/j.phrs.2015.12.031

78. Scarpignato C, Dolak W, Lanas A, Matzneller P, Renzulli C, Grimaldi M et al. Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. Gastroenterology. 2017;152(5):980-982.e3. DOI: 10.1053/j.gastro.2016.12.007

79. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. Journal of Gastroenterology. 2011;46(7):894– 905. DOI: 10.1007/s00535-011-0410-1

80. Suzuki T, Masui A, Nakamura J, Shiozawa H, Aoki J, Nakae H et al. Yogurt Containing Lactobacillus gasseri Mitigates Aspirin-Induced Small Bowel Injuries: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Digestion. 2017;95(1):49–54. DOI: 10.1159/000452361

81. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330–93. DOI: 10.1093/eurheartj/ehy136